Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company focused on developing treatments for debilitating neurodegenerative and neurodevelopmental diseases. The Company’s lead product candidate, ANAVEX®2-73 is undergoing four mid- to late-stage clinical trial programs for CNS diseases where no good treatment options exist, or current treatments are inadequate. These include Alzheimer’s disease (Phase 2b/3) and Parkinson’s disease dementia (Phase 2), which are neurodegenerative diseases that are on the rise due to aging populations in developed nations. Additionally, Anavex has two ongoing Phase 2 trials for Rett syndrome, a neurodevelopmental disease that mostly affects young female girls. Anavex has received Orphan Drug Designation from both the FDA and EMA for Rett syndrome. ANAVEX®2-73 has potential to treat other CNS disorders, given its ability to restore upstream cellular homeostasis. Anavex has received funding from Rett Syndrome Foundation, as well as Michael J Fox Foundation supporting Anavex’s studies. Anavex has identified a novel biomarker signature (genetic variants) that have potential to determine which patients will benefit the most from ANAVEX®2-73, which targets the Sigma-1 receptor (SIGMAR1), a natural cell signaling pathway that is activated to restore cellular homeostasis.
View Top Employees from Anavex Life SciencesWebsite | http://www.anavex.com |
Ticker | AVXL |
Revenue | $255000 |
Employees | 49 (42 on RocketReach) |
Founded | 2004 |
Address | 630 5th Ave Fl 20, New York, New York 10111, US |
Phone | (800) 689-3939 |
Technologies |
JavaScript,
HTML,
PHP
+18 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Drug Discovery, Business Services, Biotechnology |
Web Rank | 5 Million |
Keywords | Anavex Life Sciences Corp, Trading Site |
Competitors | Affectis Pharmaceuticals, Cerecor, Inc., ManRos Therapeutics, Minerva Neurosciences, Soligenix, Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 541712 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 54171 Companies, NAICS Code 541711 Companies |
Looking for a particular Anavex Life Sciences employee's phone or email?
The Anavex Life Sciences annual revenue was $255000 in 2024.
Stephan Toutain is the COO of Anavex Life Sciences.
42 people are employed at Anavex Life Sciences.
Anavex Life Sciences is based in New York, New York.
The NAICS codes for Anavex Life Sciences are [5417, 541712, 541, 54, 54171, 541711].
The SIC codes for Anavex Life Sciences are [28, 283].